Used as an antiplatelet agent in the management of acute coronary syndrome, including unstable angina and non-ST-elevation myocardial infarction. It is typically administered intravenously to prevent platelet aggregation during percutaneous coronary interventions. By inhibiting the glycoprotein IIb/IIIa receptors on platelets, it reduces the risk of thrombotic complications in high-risk patients. Often used in combination with heparin and aspirin for enhanced antithrombotic effect.